复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择

doi:10.35541/cjd.20210850

Abstract

Abstract: 【Abstract】 With the advances in research on cutaneous T cell lymphomas （CTCL）, some new strategies, such as traditional targeted drugs, immune checkpoint inhibitors, histone deacetylase inhibitors and allogeneic hematopoietic stem cell transplantation, have emerged and shown favorable efficacy and safety in clinical trials. This review summarizes recent research progress in non-chemotherapeutic drugs for relapsed/refractory cutaneous T-cell lymphomas.

Key words: Lymphoma, T-cell, cutaneous, Molecular targeted therapy, Immune checkpoint inhibitor, Allogeneic hematopoietic stem cell transplantation, CAR T-cell therapy

Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei. Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas[J]. Chinese Journal of Dermatology, 2023, 56(12): 1170-1173.doi:10.35541/cjd.20210850

References ［28］

［1］	Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T⁃cell lymphomas: 2021 update on diagnosis, risk⁃stratification, and management［J］. Am J Hematol, 2021,96（10）:1313⁃1328. doi: 10.1002/ajh. 26299.
［2］	Kim YH, Bagot M, Pinter⁃Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T⁃cell lymphoma （MAVORIC）: an international, open⁃label, randomised, controlled phase 3 trial［J］. Lancet Oncol, 2018,19（9）:1192⁃1204. doi: 10. 1016/S1470⁃2045（18）30379⁃6.
［3］	Chen L, Carson KR, Staser KW, et al. Mogamulizumab⁃associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response［J］. JAMA Dermatol, 2019,155（8）:968⁃971. doi: 10.1001/jamadermatol.2019.0369.
［4］	Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician′s choice in CD30⁃positive cutaneous T⁃cell lymphoma （ALCANZA）: an international, open⁃label, randomised, phase 3, multicentre trial［J］. Lancet, 2017,390（10094）:555⁃566. doi: 10.1016/S0140⁃6736（17）31266⁃7.
［5］	Papadavid E, Pappa V, Kapniari E, et al. Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicenter European EORTC study ［J］. European Journal of Cancer, 2019,119:S34⁃S35. doi: 10.1016/S0959⁃8049（19）30604⁃5.
［6］	Bagot M, Porcu P, Marie⁃Cardine A, et al. IPH4102, a first⁃in⁃class anti⁃KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T⁃cell lymphoma: an international, first⁃in⁃human, open⁃label, phase 1 trial［J］. Lancet Oncol, 2019,20（8）:1160⁃1170. doi: 10.1016/S1470⁃2045（19）30320⁃1.
［7］	Bagot M, Kim Y, Zinzani P L, et al. Lacutamab in patients （PTS） with advanced mycosis fungoides （MF） according to KIR3DL2 expression: early results from the tellomak phase 2 trial ［J］. Hematological oncology, 2021,39（Suppl 2）:97⁃98. doi: 10.1002/hon.2879.
［8］	Sawas A, Elgedawe H, Vlad G, et al. Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody （AFM13） in relapsed or refractory CD30⁃positive lymphoma with cutaneous presentation: a biomarker phase Ib/IIa study （NCT03192202）［J］. Blood, 2019,37（Suppl 2）:314⁃316.doi:10.1182/blood⁃2018⁃99⁃115269.
［9］	Pérez C, Mondéjar R, García⁃Díaz N, et al. Advanced⁃stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor⁃κB and nuclear factor of activated T cells pathways［J］. Br J Dermatol, 2020,182（1）:147⁃155. doi: 10.1111/bjd.18098.
［10］	Moskowitz A J, Ghione P, Jacobsen E D, et al. Final results of a phase II biomarker⁃driven study of ruxolitinib in relapsed and refractory T⁃cell lymphoma ［J］. Blood, 2019,134:4019. doi:10.1182/blood⁃2019⁃125017.
［11］	Karagianni F, Piperi C, Mpakou V, et al. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T⁃cell Lymphoma［J/OL］. PLoS One, 2021,16（3）:e0248298. doi: 10. 1371/journal.pone.0248298.
［12］	Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study［J］. J Clin Oncol, 2020,38（1）:20⁃28. doi: 10.1200/JCO.19.01056.
［13］	Shin J, Ho Lee D, Lee WJ, et al. Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report［J］. Melanoma Res, 2020,30（5）:515⁃518. doi: 10.1097/CMR.0000000000000664.
［14］	Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study［J］. J Clin Oncol, 2016,34（23）:2698⁃2704. doi: 10.1200/JCO.2015.65.9789.
［15］	Querfeld C S, Tsai N C, Palmer J, et al. Phase 1 results of anti⁃PD⁃ligand 1 （DURVALUMAB） & lenalidomide in patients with cutaneous T cell lymphoma and correlation with gene expression profile ［J］. Hematological oncology, 2021,39（Suppl 2）:296⁃297.doi:10.1002/hon.2880.
［16］	Bar⁃Sela G, Bergman R. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma［J］. JAAD Case Rep, 2015,1（2）:99⁃100. doi: 10.1016/j.jdcr.2015.02. 009.
［17］	Xiao M, Hennessey D, Iyer A, et al. Transcriptomic changes during stage progression of mycosis fungoides［J］. Br J Dermatol, 2022,186（3）:520⁃531. doi: 10.1111/bjd.20760.
［18］	Herrera A, Cheng A, Mimitou EP, et al. Multimodal single⁃cell analysis of cutaneous T⁃cell lymphoma reveals distinct subclonal tissue⁃dependent signatures［J］. Blood, 2021,138（16）:1456⁃1464. doi: 10.1182/blood.2020009346.
［19］	Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K⁃δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T⁃cell lymphoma［J］. Blood, 2018,131（8）:888⁃898. doi: 10.1182/blood⁃2017⁃08⁃802470.
［20］	Huen A, Haverkos BM, Zain J, et al. Phase I/Ib study of tenalisib （RP6530）, a dual PI3K δ/γ inhibitor in patients with relapsed/refractory T⁃cell lymphoma［J］. Cancers （Basel）, 2020,12（8）doi: 10.3390/cancers12082293.
［21］	Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T⁃cell lymphoma［J］. Blood, 2015,126（3）:328⁃335. doi: 10.1182/blood⁃2015⁃02⁃629543.
［22］	Bresin A, Cristofoletti C, Caprini E, et al. Preclinical evidence for targeting PI3K/mTOR signaling with dual⁃inhibitors as a therapeutic strategy against cutaneous T⁃cell lymphoma［J］. J Invest Dermatol, 2020,140（5）:1045⁃1053.e6. doi: 10.1016/j.jid. 2019.08.454.
［23］	Shi Y, Dong M, Hong X, et al. Results from a multicenter, open⁃label, pivotal phase II study of chidamide in relapsed or refractory peripheral T⁃cell lymphoma［J］. Ann Oncol, 2015,26（8）:1766⁃1771. doi: 10.1093/annonc/mdv237.
［24］	何杏兰, 王艺萌, 王冠钰, 等. 西达本胺联合苦参碱对皮肤T细胞淋巴瘤细胞系增殖、凋亡的影响及可能的凋亡机制［J］. 中华皮肤科杂志, 2020,53（2）:121⁃127. doi: 10.35541/cjd.2019 0906.
［25］	谷晓广, 吴芳妮, 张芊, 等. 西达本胺联合姜黄素对人皮肤T细胞淋巴瘤细胞系Hut78的影响及其分子机制［J］. 中华皮肤科杂志, 2016,49（2）:112⁃118. doi: 10.3760/cma.j.issn.0412⁃4030.2016.02.008.
［26］	Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and Sézary syndrome［J］. Dermatol Clin, 2015,33（4）:807⁃818. doi: 10.1016/j.det.2015.05. 014.
［27］	Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta⁃analysis［J］. Biol Blood Marrow Transplant, 2020,26（1）:76⁃82. doi: 10.1016/j.bbmt.2019.08.019.
［28］	Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T⁃cell lymphoma［J］. Cancer Sci, 2021,112（6）:2426⁃2435. doi: 10.1111/cas.14906.

[1]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the application and management of therapeutic drugs for atopic dermatitis （2024） [J]. Chinese Journal of Dermatology, 2024, 57(2): 97-108.
[2]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[3]	Yang Yongting, Li Tingting, Kang Xiaojing. Biomarkers related to the treatment of melanoma with immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2023, 56(3): 278-283.
[4]	Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210536-e20210536.
[5]	Li Tingting, Kang Xiaojing. Gut microbiota and immune checkpoint inhibitor treatment of melanoma [J]. Chinese Journal of Dermatology, 2023, 56(2): 177-180.
[6]	Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2023, 56(11): 1074-1078.
[7]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 603-609.
[8]	Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies [J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636.
[9]	Ding Yuwei, Qiao Jianjun, Fang Hong. Small-molecule targeted drugs and biological agents for alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(12): 1118-1121.
[10]	Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors [J]. Chinese Journal of Dermatology, 2022, 55(11): 1026-1030.
[11]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210248-e20210248.
[12]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210442-e20210442.
[13]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2022, 0(1): 20220028-e20220028.
[14]	Ji Xiang, Wang Daguang. Biotherapy for cutaneous squamous cell carcinoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20220172-e20220172.
[15]	Gao Tianwen, Guo Weinan. Research progress in and new treatment strategies for melanoma in China [J]. Chinese Journal of Dermatology, 2021, 54(1): 27-32.

Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［28］

Related Articles 15

Metrics

Comments

Recommended 10